OTTAWA, May 29, 2024 (GLOBE NEWSWIRE) - The federal budget, which is set to be passed before the end of June, includes changes to the Food & Drugs Act that gives the Health Minister the power (Section 326) to override regulatory approval for over-the-counter drugs, natural health products, and medical devices. The Consumer Choice Center's Toronto based David Clement explained why this new power sets Canada down a dangerous path.
"Giving the Health Minister the power to override Health Canada approvals on OTC drugs, NHPs, and medical devices creates a scenario that is ripe for ministerial abuse, with a health minister sidestepping Health Canada to regulate from a position of bias, or in response to bad headlines," said Clement.
"This power is even more problematic given the products and drugs that are covered by the change. As written, a future Health Minister could use this power to restrict access to OTC drugs like Plan B, or contraception like IUDs, and do so entirely at their discretion," said Clement.
"If the Liberals are truly committed to ensuring that women have access to certain forms of contraception, they wouldn't be giving a future Health Minister the authority and ability to override Health Canada approvals. By giving future Health Ministers this power they are setting the table for restrictions," said Clement.
***CCC North American Affairs Manager David Clement is available to speak with accredited media on consumer regulations and consumer choice issues. Please send media inquiries to david@consumerchoicecenter.org.***
The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.
CONTACT:
David Clement
Consumer Choice Center
david@consumerchoicecenter.org
905-220-0704
-
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cVANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a di2024-06-17
-
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market InfrastructureTechnology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products2024-06-17
-
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准,成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報2024-06-17
-
促进生育,助力三胎——“三胎免费生”联合公益行动正式启动为积极响应国家号召实施三胎生育政策,扩大妇幼服务健康供给,在云南省优生优育妇幼保健协会指导下,昆明广播电视台联合昆明安琪儿妇产医院,于6月13日在昆明广播2024-06-17
-
学党史传承红色精神 守党纪筑牢自律防线——平安养老险湖南分公司党支部开展主题党日活动七一前夕,平安养老险湖南分公司党支部全体成员走进“千年学府、百年师范”——湖南第一师范,开展了一次学史明理、学史增信、学史崇德、学史力行的主题党日活动。重2024-06-17